Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.61 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | GOT1 | P17174 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29362265 | 1.00 | P2RX7 (0.61) | P2RX7AHRKMT2AMEN1SNCA | |
| Hydrochloric Acid SCHEMBL30601969 | 0.98 | P2RX7 (0.59) | P2RX7AHRKMT2AMEN1SNCA | |
| Oxalic Acid SCHEMBL30601976 | 0.95 | P2RX7 (0.56) | P2RX7AHRKMT2AMEN1SNCA | |
| Sulfuric Acid SCHEMBL30601991 | 0.94 | P2RX7 (0.54) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL30601973 | 0.94 | P2RX7 (0.54) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL1403853 | 0.87 | P2RX7 (0.67) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL1412900 | 0.77 | P2RX7 (0.69) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL14574955 | 0.76 | ALDH1A1 (0.55) | KMT2ACES1 | |
| SCHEMBL109491 | 0.76 | P2RX7 (1.00) | P2RX7AHRKMT2AMEN1SNCA | |
| SCHEMBL22290176 | 0.75 | P2RX7 (0.66) | P2RX7AHRKMT2AMEN1SNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143180-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2022017494-A1 | CRYSTAL FORM OF PYRIDAZINE DERIVATIVE FREE BASE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-01-27 | — | — | WO | claimed |
| WO-2021222153-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-04 | — | — | WO | claimed |
| US-20260125361-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LTD (GB) | 2026-02-26 | — | — | US | disclosed |
| EP-4461734-B1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4640673-A1 | NOVEL AROMATIC RING DERIVATIVE CONTAINING AMIDE SUBSTITUTION AND USE THEREOF | Tianjin Pharmaceutical Biotechnology Co., Ltd (CN) | 2025-10-29 | — | — | EP | disclosed |
| US-20250179022-A1 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | SHANGHAI ZHIGEN PHARMACEUTICAL & TECHNOLOGY CO. LTD. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4488268-A1 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | Shanghai Zhigen Pharmaceutical & Technology Co. Ltd. (CN) | 2025-01-08 | — | — | EP | disclosed |
| EP-4480953-A2 | TYK2 INHIBITORS AND USES THEREOF | Alumis Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12129245-B2 | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-29 | — | — | US | disclosed |
| WO-2022241173-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022175752-A1 | TYK2 INHIBITORS AND USES THEREOF | SUDO BIOSCIENCES LIMITED (GB) | 2022-08-25 | — | — | WO | disclosed |
| US-20220259183-A1 | CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE | BRISTOL-MYERS SQUIBB COMPANY | 2022-08-18 | — | — | US | disclosed |
| US-20220235035-A1 | TYK2 INHIBITORS AND USES THEREOF | ALUMIS INC. | 2022-07-28 | — | — | US | disclosed |
| WO-2022017494-A1 | CRYSTAL FORM OF PYRIDAZINE DERIVATIVE FREE BASE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2022-01-27 | — | — | WO | disclosed |
| WO-2021222153-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-113490664-A | TYK2 inhibitors and uses thereof | 埃斯克疗法股份有限公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3873892-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | Bristol-Myers Squibb Company (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2020156311-A1 | PYRIDAZINE DERIVATIVE INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF | 江苏豪森药业集团有限公司 | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235035-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK2 | P2RX7 3234/4885AHR 957/4885KMT2A 42/4885 |
| US-20250179022-A1 | COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | TYK2, WEE2, WEE1 | P2RX7 3417/4885AHR 1044/4885KMT2A 276/4885 |
| US-12129245-B2 | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3) pyridazine-3-carboxamide | HTR3C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCAPD3 | P2RX7 3982/4885AHR 3416/4885KMT2A 819/4885 |
| US-20260125361-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK1, JAK3 | P2RX7 1081/4885AHR 1730/4885KMT2A 360/4885 |
| US-20220259183-A1 | CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE | HTR3C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCAPD3 | P2RX7 3982/4885AHR 3416/4885KMT2A 819/4885 |
| US-20260055121-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, CSNK2A3, CSNK2B | P2RX7 4340/4885AHR 797/4885KMT2A 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.